Literature DB >> 24997710

Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.

R M K Stewart1, M C Briggs, J C Jarvis, J A Gallagher, L Ranganath.   

Abstract

We describe a patient with ultra-rare disease, alkaptonuria, who developed tyrosine keratopathy following nitisinone therapy of 2 mg on alternate days. His vision became impaired approximately 7 weeks following the commencement of nitisinone and ophthalmological examination at week nine showed characteristic dendritic keratopathy associated with tyrosinaemia. The corneal lesion as well as his visual symptoms normalized completely following discontinuation of nitisinone. This is the first documented report of keratopathy due to acquired tyrosinaemia due to very low-dose nitisinone.

Entities:  

Year:  2014        PMID: 24997710      PMCID: PMC4241204          DOI: 10.1007/8904_2014_307

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  17 in total

1.  BlackAorta: a rare finding at aortic valve replacement.

Authors:  Ross J Goodfellow; Jeffrey Schwartz; Ferdinand Leya
Journal:  J Invasive Cardiol       Date:  2005-03       Impact factor: 2.022

2.  Oxidation of homogentisic acid to ochronotic pigment in connective tissue.

Authors:  V G Zannoni; N Lomtevas; S Goldfinger
Journal:  Biochim Biophys Acta       Date:  1969-02-18

3.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.

Authors:  E A Lock; P Gaskin; M K Ellis; W M Provan; M Robinson; L L Smith; M P Prisbylla; L C Mutter
Journal:  Toxicol Appl Pharmacol       Date:  1996-12       Impact factor: 4.219

Review 5.  From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.

Authors:  E A Lock; M K Ellis; P Gaskin; M Robinson; T R Auton; W M Provan; L L Smith; M P Prisbylla; L C Mutter; D L Lee
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

6.  Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake.

Authors:  J D Fernstrom; R J Wurtman; B Hammarstrom-Wiklund; W M Rand; H N Munro; C S Davidson
Journal:  Am J Clin Nutr       Date:  1979-09       Impact factor: 7.045

7.  Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  S Lindstedt; E Holme; E A Lock; O Hjalmarson; B Strandvik
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

8.  Richner-Hanhart syndrome detected by expanded newborn screening.

Authors:  Thomas Meissner; Regina Christine Betz; Sandra M Pasternack; Sibylle Eigelshoven; Thomas Ruzicka; Roland Kruse; Gitta Laitenberger; Ertan Mayatepek
Journal:  Pediatr Dermatol       Date:  2008 May-Jun       Impact factor: 1.588

Review 9.  Alkaptonuria--a review of surgical and autopsy pathology.

Authors:  T R Helliwell; J A Gallagher; L Ranganath
Journal:  Histopathology       Date:  2008-03-08       Impact factor: 5.087

10.  Natural history of alkaptonuria.

Authors:  Chanika Phornphutkul; Wendy J Introne; Monique B Perry; Isa Bernardini; Mark D Murphey; Diana L Fitzpatrick; Paul D Anderson; Marjan Huizing; Yair Anikster; Lynn H Gerber; William A Gahl
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

View more
  13 in total

Review 1.  The role of nitisinone in tyrosine pathway disorders.

Authors:  Edward Lock; Lakshminarayan R Ranganath; Oliver Timmis
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

2.  Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.

Authors:  M Khedr; S Judd; M C Briggs; A T Hughes; A M Milan; R M K Stewart; E A Lock; J A Gallagher; L R Ranganath
Journal:  JIMD Rep       Date:  2017-09-24

3.  Nitisinone-Induced Keratopathy in Alkaptonuria: A Challenging Diagnosis Despite Clinical Suspicion.

Authors:  Andrew White; Michel C Tchan
Journal:  JIMD Rep       Date:  2017-09-07

4.  Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.

Authors:  J B Mistry; D J Jackson; M Bukhari; A M Taylor
Journal:  Clin Rheumatol       Date:  2015-05-31       Impact factor: 2.980

5.  Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.

Authors:  Mohammad S Z Ahmad; Mahmoud Ahmed; Milad Khedr; Alfredo Borgia; Andrea Madden; Lakshminarayan R Ranganath; Stephen Kaye
Journal:  JIMD Rep       Date:  2022-04-09

6.  Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.

Authors:  Andrew S Davison; Brendan P Norman; Hazel Sutherland; Anna M Milan; James A Gallagher; Jonathan C Jarvis; Lakshminarayan R Ranganath
Journal:  Metabolites       Date:  2022-05-25

Review 7.  Acute fatal metabolic complications in alkaptonuria.

Authors:  A S Davison; A M Milan; J A Gallagher; L R Ranganath
Journal:  J Inherit Metab Dis       Date:  2015-11-23       Impact factor: 4.982

8.  Activation of Tyrosine Metabolism in CD13+ Cancer Stem Cells Drives Relapse in Hepatocellular Carcinoma.

Authors:  Li Sun; Lin Zhang; Jun Chen; Chaoqun Li; Hongqin Sun; Jiangrong Wang; Hong Xiao
Journal:  Cancer Res Treat       Date:  2019-12-27       Impact factor: 4.679

9.  Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.

Authors:  Haaike Colemonts-Vroninks; Jessie Neuckermans; Lionel Marcelis; Paul Claes; Steven Branson; Georges Casimir; Philippe Goyens; Geert A Martens; Tamara Vanhaecke; Joery De Kock
Journal:  Genes (Basel)       Date:  2020-12-22       Impact factor: 4.096

10.  Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.

Authors:  Juliette H Hughes; Peter J M Wilson; Hazel Sutherland; Shirley Judd; Andrew T Hughes; Anna M Milan; Jonathan C Jarvis; George Bou-Gharios; Lakshminarayan R Ranganath; James A Gallagher
Journal:  J Inherit Metab Dis       Date:  2020-01-13       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.